US Patent US10555556B2 declared invalid in infringement case

Sep.21.2022
US Patent US10555556B2 declared invalid in infringement case
Philip Morris lost patent infringement case in the US and its patent was invalidated, impacting e-cigarette product development.

Recently, in Case No.1:20-cv-0039-LO-TCB, Phimosis International accused R.J. Reynolds of patent infringement with No.US10555556B2, but the patent has since been invalidated in the U.S. after a lengthy legal battle that ended in Phimosis International's defeat. What does this ruling mean for the development of domestic electronic cigarette products?


Author bio: Lawyer Tang Shunliang is a specialized attorney in the field of new tobacco at the Beijing Zhong Lun Wen De Kunming law firm.


Part 1: Case Review


In case number 1:20-cv-0039-LO-TCB, R.J. Reynolds has brought a lawsuit against Phimow International for copyright infringement. Phimow International has responded by countersuing R.J. Reynolds for a series of patent infringement cases, highlighting the intense nature of the patent litigation between these two parties.


The case identifier is 1:20-cv-0039-LO-TCB.


On June 15, 2022, the Eastern District Court of Virginia ruled that R.J. Reynolds had infringed on two electronic cigarette technology patents owned by Philip Morris, identified as No. US9814265 and No. US10104911. As a result, they were ordered to pay $10.76 million in damages.


In this case, Phemo International has presented several weapons in its charge of infringement, including the patent No. US10555556B2, and has provided extensive evidence and reasoning to accuse VUSE VIBE of continuous infringement since June 29, 2022, specifically violating the first right claim of the patent. If this charge is proven, the compensation amount will not be limited to 10.76 million.


The R.J. Reynolds company has responded by stating that the patent should not have been granted. This is why there is now news of the recent invalidation of the patent.


Phimo International files a counter lawsuit against R.J. Reynolds for patent infringement of No.US10555556B2.


In its lawsuit, Philip Morris International compared its product VUSE VIBE to the patent No.US10555556B2 and argued that VUSE VIBE falls within the protection scope of "claim 1". However, the lawsuit fails to provide a comparison of whether VUSE VIBE contains the "first and second capillary" related technical features. Even if the patent is not found to be "invalid", it may still not constitute infringement (interested readers can download and read the legal documents).


Previously, Philip Morris International launched a patent lawsuit against British American Tobacco in Germany using patent "EP2282649," which is similar to a capillary oil guide. The court ruled in favor of British American Tobacco, stating that there was no infringement, resulting in Philip Morris International losing the case.


What is the technology solution protected by Claim 1 of patent No.US10555556B2?


A cylinder (commonly known as an e-cigarette) used in an aerosol generation system comprises a liquid storage portion that includes a pod container to maintain the liquid aerosol formation matrix. The pod container has an opening and at least two fluidly connected components (oil guiding components) form the liquid storage portion. All e-liquids need a corresponding storage component.


The first component of the liquid storage section includes:


The first capillary material, including various oil-conducting materials, fiber such as cotton, porous materials like ceramics, is used to evenly distribute the heat generating element for the e-cigarette. It is located near the opening of the shell. The second capillary material comes into contact with the first material and is separated from the opening by the first material (and does not come into contact with the heating sheet). Additionally, the second component of the liquid storage portion includes:


This refers to a device that utilizes an aerosol-forming matrix (e-liquid) to maintain a liquid state and supply the resulting aerosol-forming matrix to a container (e-liquid reservoir) made of a second capillary material. The device includes a fluid-permeable heating element (e-liquid permeator) that extends over the opening of the shell and the average pore size or porosity of the first capillary material is smaller than that of the second capillary material.


The key issue addressed by this patent is:


By setting up two guiding capillaries, the e-liquid is evenly distributed and atomized in the heater, ensuring no waste or reductions in e-liquid due to a decrease in volume or change in angle. This guarantees a high-quality vaping experience with every puff.


2.2 Common oil leakage issues have been resolved. However, the corresponding Mesh products still suffer from oil leakage problems.


The key technology of this plan is:


The use of two different types of oil-conducting materials achieves an even distribution of e-liquid to the heating element according to the frequency of vaping, resulting in improved vaporization efficiency. Claim 1 is not limited to a specific structural form and various forms and materials of oil-conducting materials and heaters are given as examples, making the scope of the invention broad. The technical solution provided in the manual is worth studying and learning from, and perhaps even finding better improvements. To aid readers in analysis, the figures have been marked by the author.


Figure 1 shows the overall technical plan, taking reference from Mesh and IQOS VEEV e-cigarettes. The core principle of oil storage, oil delivery and atomization is presented in Figure 2. Figure 3 illustrates the axial flow of oil passing through the heater and being uniformly released as smoke through the porous ceramic. Figure 4 demonstrates the radial oil delivery system (similar to traditional cotton core + metal wire) for atomization.


Closing Remarks


The ongoing patent wars between two tobacco giants indicate that both HNB and electronic vaporizer companies may continue to face legal challenges. It is possible that tobacco corporations have not yet turned their attention to Chinese electronic cigarette manufacturers, possibly due to other priorities.


However, their weapons arsenal is indeed very extensive, their research and development speed is very fast, and they are constantly laying out new patents.


Attachment 1: Global Distribution of Patents in the Same Cluster


Attachment 2: Patent Texts from Various Countries


Attachment 3: US Patent and Trademark Office invalidity decision.


Statement:


1. This article is intended for internal research and communication within the industry. It does not provide any investment or brand recommendations. This article should not be used as the basis for any investments. 2. The data and analysis conclusions mentioned in this article have not been confirmed in writing with the companies involved. Therefore, all information should be verified with official company releases.


This article is an original creation of 2FIRSTS Technology Co. Ltd. in Shenzhen. The copyright and usage rights belong to the company and no individual or organization is allowed to use, reproduce or copy the content for commercial purposes without authorization. Any infringement of the company's copyright will be subject to legal action.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Russia's State Duma Passes Tobacco and Nicotine Ingredient Disclosure Bill, Targeting 2027 End to Trade-Secret Protection for Certain Harmful Ingredient Data
Russia's State Duma Passes Tobacco and Nicotine Ingredient Disclosure Bill, Targeting 2027 End to Trade-Secret Protection for Certain Harmful Ingredient Data
Russia's State Duma passed a government-sponsored amendment on November 11, 2026, by 414 votes to none, seeking to prevent businesses from classifying information on the presence and number of types of certain harmful ingredients in tobacco and nicotine-containing products as trade secrets. The measure covers ingredients capable of increasing nicotine dependence or exhibiting toxic, carcinogenic, mutagenic or reproductive toxicity, including substances that acquire such properties during heating or smoldering. Bill No. 1286415-8 would amend Article 5 of Federal Law No. 98-FZ on Commercial Secrets and is scheduled to take effect on January 1, 2027. The bill has cleared all three readings in the State Duma but has not completed the remaining legislative procedures.
Regulations
Nov.12 by 2Firsts Perspectives
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Russia has placed shares in four Japan Tobacco International businesses under temporary management, the first such move involving a major global tobacco manufacturer, according to Interfax. JTI held 35.8% of Russia's tobacco market by volume in the first nine months of 2026. While British American Tobacco and Imperial Brands have exited Russia, Philip Morris International continues operating there. As the market changes and diplomatic efforts continue, could international tobacco companies that left Russia eventually return?
Nov.06
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Holdings Limited will acquire 100% of PT Broad Far Indonesia through two wholly owned subsidiaries for approximately RMB 90 million. The Indonesian company manufactures and sells heat-not-burn tobacco sticks and provides OEM/ODM services. The sellers are part of a related-party group controlled by Huabao International Chair and controlling shareholder Zhu Linyao. PT Broad Far Indonesia generated $4.37 million in revenue and $177,000 in profit after tax in the first half of 2026, while net assets stood at about $326,000 at June-end. An independent valuer assessed the company’s equity at approximately RMB 93.06 million. Following completion, the HNB manufacturing operation will be consolidated into Huabao International.
News
Sep.29 by 2Firsts Perspectives
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
U.S. Military Could Test Nicotine Pouches and Vapes for Smoking Cessation as Washington Examiner Cites ZYN and Potential $4 Billion Reduction in Related Defense Costs
The House-passed FY2027 National Defense Authorization Act includes a provision authorizing the defense secretary to conduct a one-year smoking-cessation pilot for active-duty service members. Section 707 lists counseling, nicotine gum and patches alongside what the bill calls "electric nicotine delivery systems," nicotine pouches and heat-not-burn products. A recent Washington Examiner op-ed cited ZYN as an example in arguing for the provision, but the legislation does not name any commercial brand or supplier. ZYN is made by PMI-owned Swedish Match USA, with specified products holding FDA marketing authorizations and modified risk orders.
Sep.20
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07